Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: A randomized controlled pilot trial

Scott G. Louis, Philbert Y. Van, Gordon M. Riha, Jeffrey S. Barton, Nicholas R. Kunio, Samantha J. Underwood, Jerome A. Differding, Elizabeth Rick, Enrique Ginzburg, Martin A. Schreiber

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: The incidence of deep venous thrombosis (DVT) remains high in general surgery and trauma patients despite widespread prophylaxis with enoxaparin. A recent study demonstrated decreased incidence of DVT if patients on enoxaparin had a change in R time (ΔR) of greater than 1 minute when heparinase-activated thromboelastography (TEG) was compared with normal TEG. We hypothesized that using ΔR-guided dosing would result in decreased DVT rates. Methods: A prospective, randomized controlled trial was performed at a Level 1 trauma center. Both trauma and general surgery patients were included. Upon enrollment, demographic data including age, sex, body mass index, and Acute Physiology and Chronic Health Evaluation II score were obtained. Enrolled patients were randomized to standard (30 mg twice a day) or TEG-guided dosing. Dose-adjusted patients underwent daily enoxaparin titration to achieve an ΔR of 1 minute to 2 minutes. Venous thromboembolism screening was performed per institutional protocol. Antithrombin III (AT-III) and anti-Xa levels were drawn at peak enoxaparin concentrations. Results: A total of 87 patients were enrolled. There was no difference in demographic data between the groups. No pulmonary emboli were identified. The control group had a DVT rate of 16%, while the experimental group had a rate of 14% (p = nonsignificant). The experimental group's median enoxaparin dosage, 50 mg twice a day, was significantly higher than that of the control (p < 0.01). TEG ΔR was not different between the control and experimental groups. Beginning at Day 3, anti-Xa levels were higher in the experimental group (p < 0.05). There was no difference in AT-III activity between the two groups; 67% of the patients demonstrated AT-III deficiency. Conclusion: TEG adjusted enoxaparin dosing led to significant increases in anti-Xa activity, which did not correlate with a decreased DVT rate. Failure to reduce the DVT rate and increase ΔR despite increased dosing and increased anti-Xa activity is consistent with the high rate of AT-III deficiency detected in this study cohort. These data suggest that the future of DVT prevention may not lie in the optimization of low molecular weight heparin therapy but rather in compounds that increase antithrombin directly or operate independently of the AT-III pathway. LEVEL OF EVIDENCE: Therapeutic study, level III.

Original languageEnglish
Pages (from-to)937-943
Number of pages7
JournalJournal of Trauma and Acute Care Surgery
Volume76
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Enoxaparin
Thrombelastography
Venous Thrombosis
Randomized Controlled Trials
Antithrombin III
Antithrombin III Deficiency
Demography
Heparin Lyase
Control Groups
APACHE
Antithrombins
Trauma Centers
Low Molecular Weight Heparin
Incidence
Venous Thromboembolism
Wounds and Injuries
Embolism
Body Mass Index
Cohort Studies
Lung

Keywords

  • deep venous thrombosis
  • enoxaparin
  • Thromboelastography

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Surgery

Cite this

Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis : A randomized controlled pilot trial. / Louis, Scott G.; Van, Philbert Y.; Riha, Gordon M.; Barton, Jeffrey S.; Kunio, Nicholas R.; Underwood, Samantha J.; Differding, Jerome A.; Rick, Elizabeth; Ginzburg, Enrique; Schreiber, Martin A.

In: Journal of Trauma and Acute Care Surgery, Vol. 76, No. 4, 01.01.2014, p. 937-943.

Research output: Contribution to journalArticle

Louis, Scott G. ; Van, Philbert Y. ; Riha, Gordon M. ; Barton, Jeffrey S. ; Kunio, Nicholas R. ; Underwood, Samantha J. ; Differding, Jerome A. ; Rick, Elizabeth ; Ginzburg, Enrique ; Schreiber, Martin A. / Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis : A randomized controlled pilot trial. In: Journal of Trauma and Acute Care Surgery. 2014 ; Vol. 76, No. 4. pp. 937-943.
@article{8373420286d04326be39c1d20a07fc39,
title = "Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: A randomized controlled pilot trial",
abstract = "Background: The incidence of deep venous thrombosis (DVT) remains high in general surgery and trauma patients despite widespread prophylaxis with enoxaparin. A recent study demonstrated decreased incidence of DVT if patients on enoxaparin had a change in R time (ΔR) of greater than 1 minute when heparinase-activated thromboelastography (TEG) was compared with normal TEG. We hypothesized that using ΔR-guided dosing would result in decreased DVT rates. Methods: A prospective, randomized controlled trial was performed at a Level 1 trauma center. Both trauma and general surgery patients were included. Upon enrollment, demographic data including age, sex, body mass index, and Acute Physiology and Chronic Health Evaluation II score were obtained. Enrolled patients were randomized to standard (30 mg twice a day) or TEG-guided dosing. Dose-adjusted patients underwent daily enoxaparin titration to achieve an ΔR of 1 minute to 2 minutes. Venous thromboembolism screening was performed per institutional protocol. Antithrombin III (AT-III) and anti-Xa levels were drawn at peak enoxaparin concentrations. Results: A total of 87 patients were enrolled. There was no difference in demographic data between the groups. No pulmonary emboli were identified. The control group had a DVT rate of 16{\%}, while the experimental group had a rate of 14{\%} (p = nonsignificant). The experimental group's median enoxaparin dosage, 50 mg twice a day, was significantly higher than that of the control (p < 0.01). TEG ΔR was not different between the control and experimental groups. Beginning at Day 3, anti-Xa levels were higher in the experimental group (p < 0.05). There was no difference in AT-III activity between the two groups; 67{\%} of the patients demonstrated AT-III deficiency. Conclusion: TEG adjusted enoxaparin dosing led to significant increases in anti-Xa activity, which did not correlate with a decreased DVT rate. Failure to reduce the DVT rate and increase ΔR despite increased dosing and increased anti-Xa activity is consistent with the high rate of AT-III deficiency detected in this study cohort. These data suggest that the future of DVT prevention may not lie in the optimization of low molecular weight heparin therapy but rather in compounds that increase antithrombin directly or operate independently of the AT-III pathway. LEVEL OF EVIDENCE: Therapeutic study, level III.",
keywords = "deep venous thrombosis, enoxaparin, Thromboelastography",
author = "Louis, {Scott G.} and Van, {Philbert Y.} and Riha, {Gordon M.} and Barton, {Jeffrey S.} and Kunio, {Nicholas R.} and Underwood, {Samantha J.} and Differding, {Jerome A.} and Elizabeth Rick and Enrique Ginzburg and Schreiber, {Martin A.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/TA.0000000000000165",
language = "English",
volume = "76",
pages = "937--943",
journal = "Journal of Trauma and Acute Care Surgery",
issn = "2163-0755",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis

T2 - A randomized controlled pilot trial

AU - Louis, Scott G.

AU - Van, Philbert Y.

AU - Riha, Gordon M.

AU - Barton, Jeffrey S.

AU - Kunio, Nicholas R.

AU - Underwood, Samantha J.

AU - Differding, Jerome A.

AU - Rick, Elizabeth

AU - Ginzburg, Enrique

AU - Schreiber, Martin A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: The incidence of deep venous thrombosis (DVT) remains high in general surgery and trauma patients despite widespread prophylaxis with enoxaparin. A recent study demonstrated decreased incidence of DVT if patients on enoxaparin had a change in R time (ΔR) of greater than 1 minute when heparinase-activated thromboelastography (TEG) was compared with normal TEG. We hypothesized that using ΔR-guided dosing would result in decreased DVT rates. Methods: A prospective, randomized controlled trial was performed at a Level 1 trauma center. Both trauma and general surgery patients were included. Upon enrollment, demographic data including age, sex, body mass index, and Acute Physiology and Chronic Health Evaluation II score were obtained. Enrolled patients were randomized to standard (30 mg twice a day) or TEG-guided dosing. Dose-adjusted patients underwent daily enoxaparin titration to achieve an ΔR of 1 minute to 2 minutes. Venous thromboembolism screening was performed per institutional protocol. Antithrombin III (AT-III) and anti-Xa levels were drawn at peak enoxaparin concentrations. Results: A total of 87 patients were enrolled. There was no difference in demographic data between the groups. No pulmonary emboli were identified. The control group had a DVT rate of 16%, while the experimental group had a rate of 14% (p = nonsignificant). The experimental group's median enoxaparin dosage, 50 mg twice a day, was significantly higher than that of the control (p < 0.01). TEG ΔR was not different between the control and experimental groups. Beginning at Day 3, anti-Xa levels were higher in the experimental group (p < 0.05). There was no difference in AT-III activity between the two groups; 67% of the patients demonstrated AT-III deficiency. Conclusion: TEG adjusted enoxaparin dosing led to significant increases in anti-Xa activity, which did not correlate with a decreased DVT rate. Failure to reduce the DVT rate and increase ΔR despite increased dosing and increased anti-Xa activity is consistent with the high rate of AT-III deficiency detected in this study cohort. These data suggest that the future of DVT prevention may not lie in the optimization of low molecular weight heparin therapy but rather in compounds that increase antithrombin directly or operate independently of the AT-III pathway. LEVEL OF EVIDENCE: Therapeutic study, level III.

AB - Background: The incidence of deep venous thrombosis (DVT) remains high in general surgery and trauma patients despite widespread prophylaxis with enoxaparin. A recent study demonstrated decreased incidence of DVT if patients on enoxaparin had a change in R time (ΔR) of greater than 1 minute when heparinase-activated thromboelastography (TEG) was compared with normal TEG. We hypothesized that using ΔR-guided dosing would result in decreased DVT rates. Methods: A prospective, randomized controlled trial was performed at a Level 1 trauma center. Both trauma and general surgery patients were included. Upon enrollment, demographic data including age, sex, body mass index, and Acute Physiology and Chronic Health Evaluation II score were obtained. Enrolled patients were randomized to standard (30 mg twice a day) or TEG-guided dosing. Dose-adjusted patients underwent daily enoxaparin titration to achieve an ΔR of 1 minute to 2 minutes. Venous thromboembolism screening was performed per institutional protocol. Antithrombin III (AT-III) and anti-Xa levels were drawn at peak enoxaparin concentrations. Results: A total of 87 patients were enrolled. There was no difference in demographic data between the groups. No pulmonary emboli were identified. The control group had a DVT rate of 16%, while the experimental group had a rate of 14% (p = nonsignificant). The experimental group's median enoxaparin dosage, 50 mg twice a day, was significantly higher than that of the control (p < 0.01). TEG ΔR was not different between the control and experimental groups. Beginning at Day 3, anti-Xa levels were higher in the experimental group (p < 0.05). There was no difference in AT-III activity between the two groups; 67% of the patients demonstrated AT-III deficiency. Conclusion: TEG adjusted enoxaparin dosing led to significant increases in anti-Xa activity, which did not correlate with a decreased DVT rate. Failure to reduce the DVT rate and increase ΔR despite increased dosing and increased anti-Xa activity is consistent with the high rate of AT-III deficiency detected in this study cohort. These data suggest that the future of DVT prevention may not lie in the optimization of low molecular weight heparin therapy but rather in compounds that increase antithrombin directly or operate independently of the AT-III pathway. LEVEL OF EVIDENCE: Therapeutic study, level III.

KW - deep venous thrombosis

KW - enoxaparin

KW - Thromboelastography

UR - http://www.scopus.com/inward/record.url?scp=84897097205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897097205&partnerID=8YFLogxK

U2 - 10.1097/TA.0000000000000165

DO - 10.1097/TA.0000000000000165

M3 - Article

C2 - 24662855

AN - SCOPUS:84897097205

VL - 76

SP - 937

EP - 943

JO - Journal of Trauma and Acute Care Surgery

JF - Journal of Trauma and Acute Care Surgery

SN - 2163-0755

IS - 4

ER -